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POPULAR SCIENTIFIC SUMMARY 
Cardiovascular diseases (CVDs) are the first cause of death worldwide, accounting for over 
17.7 million deaths alone per year (more than 31% of all deaths). This group of diseases often 
has a common underlying cause: atherosclerosis. Atherosclerosis is characterized by the 
accumulation of fat (lipids) in the arteries that will form plaques. These plaques will partially 
block the blood flow and can rupture, leading to thrombus formation and potentially death. 
The main risk factor for atherosclerosis is high levels of the so-called “bad” cholesterol (low-
density lipoproteins, LDL), which can be obtained from a high fat diet, unhealthy habits, or 
genetic reasons, among others. The most common way to medically control cholesterol levels 
is with the use of statins (cholesterol-lowering drugs). Nevertheless, clinical events still 
occur, and new therapies must be developed in order to further control atherosclerosis 
development and its associated complications. 
One of the key steps during atherosclerosis development is the movement of white blood 
cells (leukocytes) from the circulation to the site of inflammation where the disease takes 
place. This infiltration event, named transendothelial migration of leukocytes (TEML), is a 
key step for the immune response that the body will have while trying to control the disease. 
In this thesis, the role of two specific genes, Lim domain-binding 2 (Ldb2) in paper I and 
Poliovirus receptor-related 2 (Pvrl2) in paper II, during atherosclerosis and TEML will be 
discussed. Ldb2 was found to be a general regulator of the whole migration process, while 
Pvrl2 was identified to be directly involved in the process where the white blood cells 
precisely cross from the circulation into the site where the plaques will eventually form. The 
first gene, Ldb2, was shown to have a protective role against atherosclerosis: mice lacking 
this gene had more plaques that were more unstable (more prone to rupture); while Pvrl2 was 
found to promote atherosclerosis: mice lacking Pvrl2 had fewer plaques and these were more 
stable.  
As mentioned above, the effect of cholesterol-lowering is of high importance and plays a 
major role in the development of CVDs. This effect was examined in paper III in relation to 
abdominal aortic aneurysm (AAA), a vascular disease involving enlargement of the diameter 
of the abdominal aorta often accompanied by atherosclerosis. An atherosclerotic mouse 
model in which we could selectively lower cholesterol was used. Moreover, the animals were 
treated with angiotensin II (AngII) to induce AAA. We discovered more atherosclerotic 
plaques and an increase of leukocytes when treating these animals with AngII. However, we 
did not find a high incidence of AAA in this model. This is probably because the starting 
cholesterol levels of our mice where not as high as in other common AAA animal models. 
These three papers highlight the important role of cholesterol during CVD, especially during 
atherosclerosis development and AAA. The complete understanding of the newly identified 
gene targets could set the stage for the development of new therapeutic approaches. These 
would act directly on the TEML process, thus controlling the inflammatory response and 
reducing the associated disease complications. 
ii 
RESUMEN DE DIVULGACIÓN CIENTÍFICA 
Las enfermedades cardiovasculares (CVDs) son la primera causa de muerte en el mundo, 
siendo responsables de 17.7 millones de defunciones al año (más de un tercio de todas las 
muertes). Este grupo de trastornos suele tener una causa subyacente en común: la 
aterosclerosis. La aterosclerosis se caracteriza por la acumulación de grasa (lípidos) en las 
arterias formando las llamadas placas de ateroma. Estas bloquean parcialmente la circulación 
sanguínea y pueden romperse dando lugar a la formación de trombos, e incluso llegando a 
causar la muerte.  El principal factor de riesgo para el desarrollo de aterosclerosis son altos 
niveles de “colesterol malo” (lipoproteínas de baja densidad, LDL) que proviene de una dieta 
alta en grasas, de hábitos poco saludables o por razones genéticas. El método más común 
para controlar los niveles de colesterol es el uso de estatinas. Sin embargo, a pesar de su uso 
siguen sucediendo eventos clínicos, por lo que deben desarrollarse nuevas terapias para 
controlar la evolución de la aterosclerosis y las complicaciones asociadas. 
Uno de los pasos clave durante el progreso de la aterosclerosis es el movimiento de glóbulos 
blancos (leucocitos) desde la circulación hacia el sitio de inflamación donde se está 
desarrollando la enfermedad. Esta infiltración, llamada migración de leucocitos trans-
endotelial (TEML), es un proceso clave para la respuesta immune del cuerpo al tratar de 
controlar la enfermedad. En esta tesis, se detallarán las funciones de dos genes específicos, 
Ldb2 en la publicación I, y Pvrl2 en la publicación II, durante TEML y aterosclerosis serán 
detallados. Lbd2 resultó ser un regulador general de todo el proceso migratorio, mientras que 
Pvrl2 resultó formar parte del proceso específico en el cuál los glóbulos blancos cruzan de la 
circulación a la zona donde se formarán las placas de ateroma. Ldb2 mostró una función 
protectora contra la aterosclerosis: ratones sin este gen tenían más placas y estas eran más 
inestables (más propensas a romperse); mientras que Pvrl2 resultó promover la aterosclerosis: 
ratones sin este gen tenían menos placas y estas eran más estables. 
Como mencionamos anteriormente, el efecto de reducción del colesterol es de gran 
importancia y juega un gran papel en el desarrollo de las CVDs. Este efecto fue examinado 
en la publicación III en relación al aneurisma abdominal aórtico (AAA), una enfermedad 
caracterizada por el aumento del diámetro de la aorta abdominal que suele acompañarse de 
aterosclerosis. Para ello se utilizó un modelo de ratón al que se redujeron los niveles de 
colesterol selectivamente. Para inducir AAA, se trató a los animales con angiotensina II 
(AngII). Encontramos más placas de ateroma y un aumento de leucocitos al tratar a los 
animales con AngII. Sin embargo, no encontramos una alta incidencia de AAA usando este 
modelo, probablemente por los niveles de colesterol de nuestros ratones al inicio, que no eran 
tan altos como en otros modelos típicos de AAA. 
Estos tres artículos destacan la importancia del colesterol en las CVDs, especialmente en el 
desarollo de aterosclerosis y AAA. La completa comprensión de los nuevos genes 
identificados podría constituir un avance para el desarrollo de nuevos enfoques terapéuticos 
que actuarían directamente sobre el proceso TEML controlando la respuesta inflamatoria y 
reduciendo las complicaciones asociadas a la enfermedad.  
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ABSTRACT 
Atherosclerosis is most often the main underlying cause of cardiovascular diseases (CVDs), 
accounting for more than 31% of all deaths worldwide. It is driven by the uptake of low-
density lipoproteins (LDL) by a dysfunctional arterial endothelium. It involves a complex 
interplay of genetic and cellular factors that result in an uncontrolled inflammatory response 
which can potentially be fatal. The main treatment for atherosclerosis is cholesterol-lowering 
drugs, statins. Despite their use, clinical events still occur. In this thesis, three papers 
regarding CVDs and some of the key events happening during atherosclerosis are discussed.  
In paper I the role of Lim domain-binding 2 (Ldb2) as a master regulator of transendothelial 
migration of leukocytes (TEML) during atherosclerosis was investigated. We described its 
function as a modulator of the leukocyte extravasation process using in vivo mouse models 
and in vitro systems. By examining Ldb2-deficient mice we found increased atherosclerotic 
lesions and decreased plaque stability. Their TEML activity was increased, especially 
regarding monocytes and macrophages, the principal initiators of the atherosclerotic process. 
Additionally, the role of this gene was reinforced by a functional SNP found in coronary 
artery disease (CAD) cohorts associated with increased risk of myocardial infarction (MI). 
In the following publication, paper II, we describe the function of the newly identified 
cholesterol-responsive gene Poliovirus receptor-related 2 (PVRL2) in atherosclerosis. This 
gene, as a member of the nectin family, plays a major role during TEML in the extravasation 
step. Regarding atherosclerosis development, Pvrl2-deficient mice showed fewer lesions and 
more stable plaques. An increased endothelial expression of Pvrl2 coincided with an increase 
in leukocyte gene expression, strengthening its potential role during TEML. In fact, we found 
a significant decrease in leukocyte migration in the Pvrl2-deficient mice using in vivo assays. 
Moreover, we observed its endothelial expression and cholesterol-responsiveness in humans. 
The effect of cholesterol-lowering on atherosclerosis is well established, and statins remain 
the main treatment. Since statins are prescribed to most CVD patients due to the underlying 
atherosclerosis, their specific effect on single diseases are not well studied. In paper III we 
aimed to identify the effect of angiotensin II (AngII)-induced AAA on atherosclerosis and the 
influence of cholesterol-lowering on abdominal aortic aneurysm (AAA) in an atherosclerotic 
mouse model. We found a low incidence of AAA formation after AngII infusion, possibly 
because the levels of cholesterol in our mice were not high enough. Nevertheless, AngII was 
found to enhance atherosclerosis and leukocyte infiltration, stressing the importance of the 
renin-angiotensin system on atherosclerosis and suggesting a controlling effect of cholesterol 
in the model. 
All three papers emphasize the importance of cholesterol during CVDs. Further research in 
order to elucidate the underlying mechanisms and detailed role of the identified gene targets 
could have a major impact on the development of new drugs. These could act directly on 
the TEML process, thus modulating the inflammatory response and attenuating disease 
complications. 
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1 INTRODUCTION 
The discovery of the central role of cholesterol in the development of atherosclerotic disease 
was first demonstrated by Nikolay N. Anitschkow in 1913.
1
 His experiments paved the way 
and opened an immense field of research for cardiovascular scientists. Since then enormous 
progress has been made, and every year multiple papers are published highlighting and 
adding new findings that increase the complexity of this disease.  
This introductory chapter will focus on the general characteristics of two important 
cardiovascular processes: atherosclerosis and aneurysm. It will also introduce the important 
concept of leukocyte migration during an inflammatory response. Moreover, the role of 
cholesterol and cholesterol-lowering therapies will be presented. Finally, the genes involved 
in atherosclerosis and discussed later in two of the published papers included in this thesis 
will be described. 
1.1 CARDIOVASCULAR DISEASES 
Cardiovascular diseases (CVDs) are the first cause of death worldwide, accounting for more 
than one third of all deaths every year. CVDs are defined as a group of diseases affecting the 
blood vessels and the heart, and include coronary artery disease (CAD), peripheral arterial 
disease, rheumatic heart disease, abdominal aortic aneurysm, thrombosis and cerebrovascular 
disease, among other disorders. They can lead to acute events such as myocardial infarction 
(MI) or stroke and eventually to death, mainly due to the development of atherosclerosis but 
also as a result of vessel bleeding or clot formation. Importantly, most CVDs can be 
prevented by addressing behavioral risk factors such as avoiding tobacco use, being 
physically active and having a healthy diet.
2-4
 
1.2 ATHEROSCLEROSIS 
Atherosclerosis is the chronic, progressive arterial disease underlying the development of 
CAD. It is associated with both environmental and non-environmental or genetic risk factors 
(Table 1). These factors have been identified in numerous epidemiological studies and 
include diabetes, obesity, elevated blood pressure, family history and an unhealthy lifestyle 
(lack of exercise, high-fat diet or smoking). The primary factor and pre-requisite for the 
development of the disease is elevated plasma levels of low-density lipoproteins (LDL) 
containing cholesterol, which will trigger an inflammatory response initiated by the migration 
of leukocytes from the circulation into the intima of the arterial wall. Atherosclerosis is 
clinically significant in half of the population, a number that increases when the risk factors 
accumulate, and it is responsible for 50% of all CAD deaths in Western societies.
4-7
 The 
addition of factors occur rather easily; frequently an unhealthy lifestyle already includes 
several of the other risk factors associated with developing the disease. Furthermore, these are 
commonly associated with obesity, diabetes or hypertension and usually develop into some of 
the other non-environmental factors. 
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Table 1. Risk factors associated with atherosclerosis and CAD development. 
Non-environmental factors Environmental factors 
Elevated levels of LDL and VLDL Unhealthy diet (high-fat, salt) 
Reduced levels of HDL Smoking 
Elevated levels of triglycerides Physical inactivity 
Elevated levels of lipoprotein (a) Alcohol abuse 
Elevated levels of C-reactive protein Infectious agents 
Hypertension Air pollution particles 
Metabolic syndrome  
Family history/Genetics  
Increased BMI/Obesity  
Diabetes mellitus type 2  
Male gender  
Advanced age  
 
The atherosclerotic process is initiated by interplay between endothelial dysfunction and 
retention of subendothelial lipoproteins. It is characterized by the subendothelial buildup of 
lipids and fibrous elements in the arterial intima layer which, over timer, lead to the formation 
of atherosclerotic plaques which push the intima into the lumen, narrowing the blood flow. 
The developed non-resolving inflammatory response triggers the arterial destruction of the 
intima, thrombosis, and ischemia (Figure 1).
4,8,9
 
 
Figure 1. Progression of an atherosclerotic lesion. Evolution from an early fatty streak to rupture of the plaque, 
and simplified overview of the main cell types and components involved. 
In brief, the disease develops when plasma levels of cholesterol rise and apolipoprotein-B 
(ApoB)-containing lipoproteins (mainly LDL-particles) are retained and infiltrate the arterial 
wall. These lipoproteins undergo various oxidative modifications that mimic 
pathogen/damage-associated molecular patterns that lead to the release of active 
phospholipids that will trigger an activation of the endothelium.
9,10
 This activation can also 
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occur due to a disturbed blood flow and an oscillation of shear stress in the vascular wall, 
mainly in regions of curvature or arterial branching.
11
 The activation results in the expression 
of adhesion molecules that will prompt a cascade of events, including recruitment of 
monocytes and their transmigration through the endothelium into the intima layer of the 
arterial wall, activation of vascular smooth muscle cells (SMCs), and accumulation of lipid, 
cells and extracellular material in the intimal subendothelial space. These cells include not 
only leukocytes such as monocyte-derived macrophages, T cells, dendritic cells, B cells and 
mast cells, but also SMCs that display myofibroblast characteristics.
9
 
Once monocytes have migrated into the intima in response to a gradient of monocyte 
chemoattractant protein-1, they will differentiate into macrophages upon stimulation by 
macrophage-colony-stimulating factor. This results in the upregulation of pattern recognition 
receptors (such as scavenger receptors) that will mediate the uptake of oxidized LDL and will 
eventually lead to the formation of the so-called “foam cells”. At the same time, in response 
to cytokines such as interferon gamma (INFγ), macrophages upregulate the expression of 
toll-like receptors (TLRs) which bind tumor necrosis factor alpha (TNFα) and interleukin 1 
(IL-1), and result in the release of pro-inflammatory molecules (reactive oxygen species, 
ROS; pro-inflammatory cytokines; proteases and others) (Figure 2).
4,12
 Foam cell apoptosis 
and lipid deposits, together with the exacerbated inflammation; give rise of what is known as 
an early atherosclerotic lesion or “fatty streak”, the initial stage of atherosclerosis.  
 
Figure 2. First steps in the progression of atherosclerosis. Differentiation of monocytes into macrophages, formation of 
foam cells and initiation of the inflammatory response. M-CSF: macrophage-colony-stimulating factor. ScR: scavenger 
receptor. oxLDL: oxidized LDL. 
From this moment on, the atheroma will progress into a more complex lesion including the 
formation of a necrotic core and a partial resolution process depicted by the development of a 
covering scar.
9,13,14
 The pro-inflammatory mediators released by macrophages also include 
growth factors that will stimulate the SMCs in the media, which will migrate and accumulate 
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in the lesion area and will increase the amount of extracellular matrix (ECM) and lead to the 
formation of the fibrous cap.
6,12
 This cap offers a protective barrier between the pro-
thrombotic material in the plaque and the platelets present in the circulation. Consequently, 
most atherosclerotic lesions do not result in acute vascular events.
15
 
Nevertheless, these advanced atherosclerotic lesions usually lead to a narrowing of the vessel 
lumen, which can potentially result in an ischemic event. The risk of acute events escalates 
when there is a “vulnerable plaque” with a large necrotic core resulting from a combination 
of cell necrosis and defective clearance of apoptotic cells (efferocytosis).
8
 The increase of 
apoptosis and an uncontrolled inflammatory response (activated immune innate and adaptive 
pathways) can destabilize the lesion (expression of proteases such as matrix 
metalloproteinases, MMPs; coagulation factors; free radicals and vasoactive molecules; 
defective collagen synthesis by SMCs), attack the collagen present in the fibrous cap, 
thinning and weakening it, and can eventually rupture it.
6,12,16
 Plaque rupture exposes the 
bloodstream to the lipids and tissue factor present in the lesion, initiating a coagulation 
cascade that will lead to platelet adherence and thrombus formation.
6
  
The lack of symptoms during the development of atherosclerosis results in substantial 
progression of advanced plaques that will be calcified, necrotic and close to rupture before 
any clinical events occur. The possibility of reversing the lesions at this point will then be of 
extreme difficulty. 
1.2.1 Dysfunctional endothelium: athero-protective vs. athero-prone 
The vascular endothelium can be regarded as dysfunctional when alterations in its phenotype 
occur, rendering an impaired barrier function as well as pro-inflammatory and/or pro-
thrombotic characteristics. This represents a pathogenic risk factor for numerous vascular 
diseases, as in atherosclerosis. The situation tends to happen in unique areas within the 
vasculature (“lesion-prone” areas), typically around vascular curves or branch regions, often 
triggered by biomechanical forces (low shear stress, steep flow).
9,17
 Exactly how the 
endothelium senses this biomechanical forces and discriminates flow patterns remain poorly 
described.
18
 These areas are also distinguishable by their predisposition to retain LDL 
particles, a characteristic that exacerbates the dysfunctional phenotype of the endothelium.
9,17
 
1.2.1.1 Athero-protective endothelium 
When the endothelium has certain characteristics that make it resist or protect itself against an 
inflammatory event, it is known as “athero-protective” or “athero-resistant” endothelium. The 
endothelial cells (ECs) from these areas have an ellipsoidal morphology, with the nuclear and 
cytoplasmic components aligned in the direction of the primary blood flow and a thick 
glycocalyx layer.
9,19
 Moreover, this phenotype involves differences in the gene expression of 
several transcription factors (such as Kruppel-like factors 2 and 4, KLF2 and KLF4, which 
are stimulated by the MEK5/Erk5 signaling pathway).
20,21
 The function of these activated 
transcription factors is not clearly defined in the endothelium: such is the case for KLF2. On 
the other hand, this same factor in monocytes,
22
 dendritic cells
23
 and T cells
24,25
 seems to 
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promote a general anti-inflammatory state, and in myeloid cells was shown to be athero-
protective.
26
 Instead, the other known upregulated transcription factor, KLF4, seems to have a 
much clearer athero-protective function in ECs.
27
 
1.2.1.2 Athero-prone endothelium 
Contrary to the athero-resistant endothelium, regions which seem to promote or facilitate the 
development of inflammation and atherogenesis are termed “athero-prone” or “athero-
susceptible”. ECs in these areas do not display the same pattern as the ones in the protective 
endothelium. In the athero-susceptible areas, the ECs present a cuboidal shape and show 
higher turnover rates and senescence.
9
 They also seem to express markers of chronic ER 
stress, which cause endothelial apoptosis and therefore promote atherosclerosis.
28,29
 This 
phenotype is also accompanied by gene expression alterations, in this case in the form of 
activation of the necrosis factor kappa B (NF-κB) pathway in the endothelium,30,31 which 
leads to the upregulation of vascular cell-adhesion molecule 1 (VCAM-1) and TLR2,
32
 as 
well as to an increase in pro-inflammatory chemokines, cytokines, miRNAs and ECM 
proteins.
33-37
 Disturbed flow also modifies DNA methylation patterns. For example, this turns 
into the inhibition of the transcription of the previously mentioned athero-protective KLF4 
factor in these vascular endothelial regions, rendering them more susceptible to the disease.
38
 
1.2.2 Monocytes and macrophages in atherosclerosis 
As mentioned before, endothelial activation in the early atherosclerotic lesions prompts a 
chemokine-induced influx of monocytes derived from the bone marrow that will initiate the 
inflammatory response in the intima.
39
 Occasionally, the monocytes reach the lesions after 
proliferation and activation in the spleen, often triggered by stress-induced stimulation of the 
sympathetic nervous system.
40
 From the different monocyte subtypes, the inflammatory Ly6
hi 
subset seems to enter the lesions faster, although both Ly6
hi 
and Ly6
lo
 groups accumulate 
during atherosclerosis development. While Ly6
hi 
tend to differentiate into pro-atherogenic 
macrophages, Ly6
lo
 monocytes have classically had a patrolling function in the circulation 
and their function within tissues remains unclear.
41
  
Upon monocyte stimulation and differentiation into macrophages, they undergo multiple 
phenotypic changes.
42
 These modifications contribute to segregate them into a wide spectrum 
of functional macrophages that will exert distinct roles (host defense and inflammation on 
one side of the spectrum vs. resolution and repair on the opposite flank). Inflammatory 
macrophages (classically activated “M1” subtype), in general, promote atherosclerosis 
development, while resolving macrophages (alternatively activated “M2” subtype) suppress 
atheroma progression and stimulate plaque regression.
8,43
  
Inflammatory macrophages express and secrete cytokines, proteases such as MMPs (MMP2, 
MMP9), and other factors that stimulate plaque progression, rupture and thrombosis. They 
also promote the necrosis and thinning of the fibrous protective cap. On the other hand, 
resolving macrophages stabilize plaques by secreting collagen contributing to the fibrous cap, 
stimulating efferocytosis (clearing of dead cells) and therefore preventing necrosis, and 
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generating lipids (such as resolvins and lipoxins) and proteins (IL-10; transforming growth 
factor beta, TGFβ; and annexin A1) that promote tissue repair.41,44 
Molecular profiling has shown extensive heterogeneity: macrophages belonging to both sides 
of the spectrum are found at different regions of the plaques during disease development. 
Therefore, consistently with the functions they exert, inflammatory macrophages tend to be 
concentrated in unstable plaques that are prone to rupture, while resolving macrophages 
gather within more stable and even regressing plaques.
41,45,46
 The phenotypic modulation of 
lesional macrophages remains to be thoroughly studied.  
Macrophages take up lipoproteins by a combination of phagocytosis, pinocytosis (native 
lipoproteins), and scavenger receptor-mediated internalization (modified lipoproteins).
9
 This 
cholesterol accumulation turns them into “foam cells” due to how they look after engulfing 
all those particles. It has been shown that cholesterol buildup in macrophages activates TLRs 
and stimulates the inflammasome signaling pathways, which leads to an increased production 
of inflammatory chemokines and cytokines such as IL-1β.47,48 Moreover, oxidative stress 
induced by modified LDL also stimulates inflammatory pathways such as the NF-κB 
cascade, which leads to the upregulation of monocyte chemoattractant protein-1 and a 
subsequent increase in monocyte recruitment to the plaques.
6,49
  
1.2.3 Vascular SMCs in atherosclerosis 
The layers of SMCs present in the media have the role of maintaining the muscle tone of the 
vessel and regulate their caliber, thus adjusting blood volume and blood pressure. During an 
atherosclerotic process, the SMCs are found in the intima layer of the vessel and they are 
phenotypically and functionally different from those found in the media under normal 
conditions. Moreover, the role of SMCs during the progressive stages of atherosclerosis 
seems to vary depending on the phenotypic state of these plastic cells.  
The activation of medial SMCs occurs as a result of the accumulation of lipoproteins, 
endothelial activation and inflammation in the plaques. This phenotypic modulation entails a 
transformation from fully contractile, differentiated, mature and inactive SMCs that express 
both smooth muscle alpha actin (Acta2) and smooth muscle myosin heavy chain (Myh11) to a 
“synthetic state”, a proliferating and migrating phenotype in which there has been a 
downregulation of the differentiation and the above mentioned genes. This synthetic 
phenotype is associated with an increased production of proteoglycans, ECM and other 
proteins related to vascular repair and fibrous cap stabilization. Conversely, the SMCs in this 
area may suddenly activate the expression of MMPs and inflammatory mediators and may 
undergo apoptosis. This occurs in response to not-well defined environmental signals, 
therefore changing function and promoting plaque rupture and thrombosis.
50
 
Additionally, depending on the stimuli present, the SMCs seem to specialize and modify their 
phenotype even further. Thus, oxidized LDL leads to an intermediary phenotype with 
enhanced collagen expression, proliferation and migration;
51
 TGFβ promotes a matrigenic 
phenotype associated with an increased production of ECM;
52
 and inflammatory cytokines 
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(TNFα, IL-1) enhancing the expression of adhesion molecules and MMPs, and thus 
promoting an inflammatory phenotype.
53-55
 Moreover, high levels of inorganic phosphate 
seem to boost an osteochondrogenic state which stimulates calcification.
56
 Nevertheless, there 
is a lack of lineage-tracing studies in the field which are needed in order to show whether the 
SMCs truly give rise to different phenotypes in vivo.
50
 
1.2.4 Other immune cells in atherosclerosis 
1.2.4.1 Lymphocytes 
Between 10% and 20% of the cells found in a plaque during atherosclerosis development are 
T cells.
57
 They are present during all phases of the disease, whereas B cells are found in 
smaller numbers and more often appear in the adventitia layer. Both T cells and B cells 
modulate atherosclerosis and influence plaque stability.
58
 
These cell subsets can be distinguished according to the expression pattern of surface and 
intracellular proteins, but also depending on their function (such as release of cytokines and 
interaction with other B cells or T cells and macrophages). In atherosclerotic plaques, the 
majority of T cells belong to the T helper 1 (Th1) CD4+ subset, followed by CD8+. Other 
subsets such as Th2, regulatory T cells, Th17 and natural killer T cells are also present.
58
  
Those T cells are activated and polarized in the plaques to the Th1 subset in order to regulate 
the lesion growth by producing pro-inflammatory cytokines such as TNFα and INFγ, and are 
therefore considered pro-atherogenic.
59
 Regarding Th2 function, findings are controversial, 
and although they are traditionally regarded as anti-atherogenic, some studies have found 
them to stimulate atherogenesis.
60,61
 Nevertheless, Th2 cells have an important role in B cell 
activation, plasma cell differentiation and antibody production. Likewise, natural killer T 
cells and B cells seem to have a pro-atherogenic role, although an athero-protective function 
has also been described.
62-66
 On the other hand, regulatory T cells appear to exert a more 
evident athero-protective function through the production of anti-inflammatory cytokines 
(such as TGFβ and IL-10).67-69  
In advanced lesions B cells and T cells seem to also be activated in adventitial artery tertiary 
lymphoid organs, a subject that needs further investigation.
69
 
1.2.4.2 Dendritic cells 
Dendritic cells are antigen-presenting cells that initiate and sustain immune responses, 
display a selection of antigens to the T cells and have the capacity to inhibit their activation 
and maintain immune tolerance against self-antigens (due to their expression of co-
stimulatory molecules and their cytokine production profile).
70
 Most of the dendritic cells 
during atherosclerosis progression are located in the intima.
71
 They are activated and likely 
participate in the early lesion development by internalizing oxidized LDL and becoming 
foam cells.
72,73
 Additionally, they seem to promote inflammation in later stages of the disease 
by stimulating the production of INFγ by CD4+ T cells.74 
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1.2.4.3 Neutrophils 
Neutrophils represent a significant source and an essential target for chemokines and lipid 
mediators.
75
 These polymorphonuclear leukocytes appear in the atherosclerotic plaques as 
part of the blood components of an intraplaque hemorrhage or via diapedesis in the early 
stages of disease development.
76,77
 Neutrophils are a major source of proteases that may 
contribute to plaque rupture and atherosclerosis progression. Moreover, the arrival of 
granulocytes is followed by the release of large amounts of ROS and other oxidative enzymes 
that exacerbate local oxidative stress and intensify plaque progression.
78,79
 Furthermore, high 
levels of cholesterol induce neutrophilia, which is correlated to the degree of atherosclerotic 
lesions.
80,81
 
1.2.4.4 Mast cells 
Mast cells are found in their activated form in atherosclerotic plaques. They have been 
associated with lipid accumulation (since they facilitate the degradation of high-density 
lipoproteins, HDL; and impair the efflux of cholesterol) and thus with plaque progression.
82-84
 
1.3 ABDOMINAL AORTIC ANEURYSM 
An aneurysm is a cardiovascular event that occurs when there is a permanent and 
irreversible dilation of a vessel due to weakening of the wall that involves all three vascular 
layers (intima, media and adventitia). Abdominal aortic aneurysms (AAAs) are the most 
common type of aortic aneurysms. They develop in the infra-renal segment of the 
abdominal aorta and are defined as aneurysm when the aortic diameter exceeds the normal 
diameter by 50%. They are usually asymptomatic and, if left untreated, result in eventual 
aortic rupture and mortality in 85-90% of the cases (Figure 3). The rupture occurs when the 
mechanical forces on the wall (blood pressure, shear stress) exceed its strength.
85
 A number 
of risk factors have been associated with the incidence of AAA including tobacco use, 
advanced age, male sex, hypertension, overweight, family history and hardening of the 
arteries. Oppositely, the presence of diabetes mellitus is known to be protective against the 
development of AAA. Aneurysms are also associated with atherosclerosis, transmural 
degenerative processes, neovascularization, degeneration of SMCs and chronic 
inflammation in the outer aortic wall; however the mechanisms that stimulate the initiation 
of AAA are still poorly understood.
85-89
 
 
Figure 3. Schematic view of the 
progression of an abdominal aortic 
aneurysm. An AAA is developed when 
the normal diameter of the aorta 
increases 50% and can eventually lead to 
rupture of the wall. 
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The integrity of the vessel wall depends on the well-adjusted remodelling of the ECM and 
its components (elastin, collagen and SMCs). There are four distinct pathological events in 
the development of AAA: infiltration of leukocytes, destruction of collagen and elastin 
mediated by proteases (such as matrix metalloproteases, MMPs), loss of SMCs, and 
neovascularization. The initiation of an aneurysm involves the infiltration of leukocytes as a 
local inflammatory response. These leukocytes are associated with an increased production 
of ROS, inflammatory cytokines and chemokines which, in combination with leukotrienes 
and immunoglobulins, lead to loss of elastin and collagen, an upregulation of local adhesion 
molecules, SMC apoptosis and neovascularization.
85,87,88,90,91
 Adventitial collagen is 
responsible for the resistance of the aorta in the absence of elastin in the media: when the 
collagen turnover is not enough to compensate for its loss (meaning there is an imbalance 
between synthesis and degradation), it may result in further dilation of the vascular wall and 
the risk of rupture increases exponentially (Figure 4).
86,90,91
 
 
Figure 4. Biochemical and proteolytic events in AAA. 
The development of AAA is also associated with mural thrombus formation. Aortic blood 
flow is maintained, in contrast with other occlusive cardiovascular diseases like 
atherosclerosis, which results in a continuous remodelling of the components of the 
thrombus.
86
 This thrombus also acts as a source of proteases, since the neutrophils present 
therein store MMPs; and it also contains plasminogen which can result in local generation 
of the MMP activator plasmin.
92
 The increasing thickness of the wall induces local hypoxia 
in the media, causing increased medial neovascularization and resulting in further 
inflammation.
93
 
1.4 TRANSENDOTHELIAL MIGRATION OF LEUKOCYTES 
The EC layer is the first obstacle leukocytes have to overcome during their recruitment to 
inflammation sites. The adhesion of leukocytes from the circulation and their consequent 
transmigration through the endothelium into the wall of blood vessels is a crucial event in the 
pathogenesis and inflammation processes of atherosclerosis and AAA. The extravasation 
cascade (commonly referred to as transendothelial migration of leukocytes, TEML), is a 
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complex multistep route that entails the activation of numerous adhesion molecules and 
signaling pathways.
94
 
In brief, when the endothelium is activated due to an inflammatory stimulus, pro-
inflammatory cytokines induce the expression of several adhesion molecules that will attract 
and recruit leukocytes.
95
 These leukocytes, assisted by their endothelial ligands, will go 
through the different steps of the TEML cascade until their complete extravasation (Figure 5). 
The key steps of the cascade start with the rolling of leukocytes which brings them close 
enough for their chemokine receptors to be activated by E-selectin and P-selectin on the 
endothelial surface.
96
 It continues with the leukocyte adhesion to the endothelial surface, a 
step facilitated by VCAM-1 and intercellular adhesion molecule 1 (ICAM-1).
97,98
 Leukocytes 
can keep crawling over the endothelium until they reach the junction where they will migrate 
through. The last step includes the diapedesis of the leukocytes (the actual transmigration 
phase) and it is the only process that is irreversible. Diapedesis occurs when the leukocytes 
move across the ECs via a transcellular route (across the EC body), or most commonly in a 
paracellular way by passing in between two ECs. This later route implies breaching the array 
of endothelial connections, namely tight junctions (TJs), adherens junctions (AJs) and gap 
junctions (GJs) that control vascular permeability and maintain the integrity of the 
endothelium.
99,100
 This phase is mediated by multiple proteins present in the different 
junctions including platelet/endothelial cell adhesion molecule 1 (PECAM-1), poliovirus 
receptor (PVR/CD155), junctional adhesion molecules (JAMs), CD99, nectins such as 
poliovirus receptor-related 2 (PVRL2), and others.
101
 Some of these molecules such as CD99 
and PECAM-1 are expressed both on the endothelium and on the leukocytes, suggesting that 
homophilic interactions occur during this migration step.  
 
Figure 5. Schematic view of the TEML adhesion cascade and some of the main players involved. 
The three dynamic endothelial junctions mentioned above consist of transmembrane and 
cytoplasmic proteins that are associated with the actin cytoskeleton (Figure 6). The TJs are 
localized in the most apical border (close to the lumen of the vessel), control the diffusion of 
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ions and prevent large macromolecules from penetrating the ECs. They include 
transmembrane proteins from the JAMs family (JAM-A, JAM-B, JAM-C and CAR), 
occludins, and claudins associated with integrins, zona ocludens 1 (ZO-1) or afadin as 
adaptors to the cytoskeleton. AJs provide mechanical strength between ECs and contain 
transmembrane nectins and VE-cadherin associated with cytosolic catenins that serve as 
anchor to the intracellular actin network. Lastly, GJs participate in endothelial cell-cell 
signaling and communication, although these junctions do not seem to contribute to TEML. 
PECAM-1 and CD99 are excluded from the TJs and GJs, and are sometimes included as non-
classical proteins belonging to the AJ system. 
99,102-104
 
 
Figure 6. Schematic view of the classical endothelial proteins participating in TJs and AJs.  
The order of events in which these proteins appear to function on the EC basolateral 
membrane seem to be quite distinct. For some of the main molecules involved, this process 
has been studied using sequential blocking experiments. In this fashion, PECAM-1 was 
shown to act first, followed by PVR/DNAM-1 (endothelium/leukocyte) and afterwards by 
CD99.
105
 These are just three of all the players involved in the complex migration process, 
which involves complicated signaling and communication mechanisms that are acting during 
all the stages of the TEML process. 
Moreover, a novel and still not completely understood structure involved in the diapedesis 
phase of TEML has been defined: the lateral border recycling compartment. This structure 
seems to form vesicles that cluster PECAM-1 and also contains JAM-A and CD99. It is 
localized close to the endothelial basolateral membrane and moves towards the sites of 
migrations during TEML.
106-108
 
Once leukocytes have passed the EC layer they have to cross through the basement 
membrane and pericytes (in venules and microvasculature) to complete extravasation. This 
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takes place via gaps in between pericytes that concur with areas of the basement membrane 
containing less ECM.
109
 
1.5 CHOLESTEROL AND LIPOPROTEIN METABOLISM  
Cholesterol is a type of dietary lipid (exogenous uptake), but also synthesized de novo in 
liver and intestine. The body requires cholesterol for vital biochemical functions (formation 
of fluid cell membranes, steroid hormone production, metabolism of vitamin D), but 
abnormalities in its metabolism, or excessive plasma levels, can lead to health 
complications.
110,111
 
The chemical formulation of cholesterol is 3-hydroxy-5,6-cholestene, and it is synthesized 
from acetyl-coA in the cytosol in three stages. In short, the first set of reactions includes the 
formation of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), which is reduced to 
mevalonate by HMG-CoA reductase, and its further conversion into isopentenyl 
pyrophosphate. The second stage concludes with the synthesis of squalene (passing through 
geranyl pyrophosphate subsequently converted to farnesyl pyrophosphate). The last stage 
comprises the cyclization of squalene to squalene epoxide, lanosterol, and finally 
cholesterol.
112
 
Cholesterol is released into the bloodstream inside the hydrophobic core of lipoproteins. 
These hydrophilic particles are secreted by the liver and small intestine in order to deliver 
cholesteryl esters, triglycerides (TGs) and phospholipids to the peripheral tissues and to 
recycle them back to the liver for clearance.
113
 The lipoproteins also contain specific 
proteins (apolipoproteins) in their membrane.  
There are five major lipoproteins, classified according to their size and density: 
chylomicrons (CMs), very low-density lipoprotein (VLDL), intermediate-density 
lipoprotein, low-density lipoprotein (LDL), and high-density lipoprotein (HDL). CMs 
contain ApoB-48 and are produced in the gastrointestinal tract using dietary lipids. They 
are transported through the lymphatic channels into the blood circulation, where they 
become remnant CMs after the removal of the TGs by the enzyme lipoprotein lipase.
114
 
While the enterocytes synthesize ApoB-48, hepatocytes in the liver synthesize ApoB-100 
and assemble VLDL with the aid of microsomal triglyceride transfer protein (MTTP).
115
 
Once secreted, the ApoB-containing lipoproteins obtain further proteins, namely ApoC-II, 
ApoC-III, and ApoE. The enclosed TGs are hydrolyzed by lipoprotein lipase, releasing free 
fatty acids for cellular uptake by peripheral tissues, and leading to the formation of smaller 
and denser lipoprotein remnants.
113
 HDL particles contain ApoA in their surface. VLDL 
and LDL transport hepatic lipids to the peripheral tissues, while HDL returns cholesterol to 
the liver where it can be excreted via bile acid metabolism.
111
 In order to do so, HDL 
interacts with cholesteryl ester transfer protein, which facilitates the exchange of 
cholesterol esters and TGs with LDL particles. The cholesterol acquired by HDL is 
excreted through the bile, and the HDL particle is either returned to the bloodstream or 
hydrolyzed.
113,116,117
 Therefore, LDL is traditionally considered as “bad cholesterol” 
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whereas HDL is considered “good cholesterol”. Furthermore, a high HDL/LDL ratio is 
linked with a decreased risk of developing heart disease. 
It is generally accepted that LDL-cholesterol particles are being deposited in the 
dysfunctional arterial wall and will initiate the atherosclerotic disease development. These 
particles are transporting the largest amount of cholesterol of all lipoproteins. The LDL 
particles bind to LDL-receptors (LDLRs) mainly in liver and intestines. The LDL, once 
bound to the LDLR, forms a complex that will be endocytosed, free cholesterol will be 
released and the receptor recycled to the cell surface. At the same time, proprotein 
convertase subtilisin/kexin type 9 (PCSK9) stimulates LDLR lysosomal degradation, 
therefore indirectly decreasing LDL clearance.
113
 
1.5.1 Cholesterol-lowering effects and CVDs 
Hyperlipidemia, and more specifically, high levels of LDL-cholesterol are, as stated earlier, 
the most important risk factor for CAD and other CVDs. The pharmacological way to 
control elevated lipid levels in patients with this disease is therefore lipid-lowering therapy.  
The main group of lipid-lowering drugs are statins (HMG-CoA inhibitors), even though 
other options are still being used. In addition, newly developed drugs such as PCSK9 
inhibitors that reduce the LDLR degradation have been recently approved for the treatment 
of homozygous familial hypercholesterolemia.
118-121
 However, nowadays statins are the 
keystone of medical treatment for dyslipidemia and do not seem to have competition in the 
market. Statins block hepatic cholesterol synthesis by inhibiting HMG-CoA reductase, 
which results in less cholesterol being released into the circulation and a decrease in the 
inflammatory response (Figure 7). They are structural analogues to HMG-CoA reductase 
and are competitive inhibitors with 1000-10000 times greater affinity for its substrate. It is 
commonly accepted that the decrease of LDL-cholesterol with statin treatment reduces the 
risk of major coronary events, ischemic stroke and revascularization, and stabilizes the 
fibrous cap.
118
 However, residual cardiovascular risks, even with high doses of statins, 
remain high and additional LDL-cholesterol lowering therapies are needed. 
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Figure 7. Schematic diagram showing the various functions of statins. PI-3K: phosphoinositide-3-kinase; Akt: protein 
kinase B; eNOS: endothelial nitric oxide synthase; NADP oxidase: nicotinamide adenine dinucleotide phosphate oxidase; 
MAP kinase: mitogen-activated protein kinase. 
1.5.1.1 Atherosclerosis and cholesterol-lowering therapy 
The accumulation of modified LDL-cholesterol in the arterial wall leads to the formation of 
foam cells contributing to the pathogenesis and development of atherosclerotic plaques. A 
reduction in plasma LDL-cholesterol levels has been shown to slow its progression. Statins 
have proven to decrease the cardiovascular events in patients with atherosclerosis. Several 
studies have shown that high-dose statin treatment not only decreases progression, but also 
induces regression of plaques.
122
 Statins seem to modify the biology of atherosclerosis 
through multiple pleiotropic effects: by indirectly lowering plasma cholesterol through 
upregulation of the LDLR; by decreasing vascular inflammation via reduction of C-reactive 
protein levels in serum; by improving the endothelial function and increasing endothelial 
nitric oxide synthase when interfering with the PI-3 kinase/Akt pathway (Figure 7); by 
increasing EC repair; by reducing the expression of pro-inflammatory molecules and 
interfering with the MAP kinase and Ras pathways; by inhibiting platelet aggregation; and 
by stabilizing atherosclerotic plaques through an increase in collagen and SMCs and 
reducing the inflammatory cell recruitment and matrix-degrading enzymes.
123,124
 Statins 
also act on macrophages, reducing their accumulation inside the plaque and downregulating 
CD36 expression, which decreases the uptake of oxidized LDL.
125,126
 
Even though statins have shown to significantly decrease the mortality and morbidity of 
CAD patients, the disease remains as the number one cause of death worldwide. Almost 1 
in 10 high-risk patients treated with an intensive statin therapy, who respond to the 
treatment with low levels of LDL-cholesterol, have still suffered from subsequent events in 
a two-year period.
127
 In addition, patients on standard statin therapy due to diagnosed 
atherosclerosis still develop a major cardiovascular event in more than 20% of the cases 
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within five years of treatment.
128
 This may be caused by the fact that there is no reasonable 
and inexpensive non-invasive imaging method that would allow the detection and 
visualization of early atherosclerotic plaque progression, inflammation and remodelling; 
meaning that most patients will not be prescribed statins until they have a cardiovascular 
event later in life. Since atherosclerosis starts to develop in the first decade (Figure 8), those 
patients will already have a substantial burden of pre-existing advanced plaques at the onset 
of cholesterol-lowering therapy. Nowadays, hybrid morphology-functional techniques such 
as PET/CT and PET/MRI are promising methods that allow the detection of high-risk 
plaques in a non-invasive way to help select patients at increased risk.
129
 Additionally, 
biomarkers of early atherosclerosis development are needed to improve the identification of 
patients who would benefit from early statin therapy. 
 
Figure 8. Timeline for the development of atherosclerosis. 
1.5.1.2 Abdominal aortic aneurysm and cholesterol-lowering therapy 
Although atherosclerosis and AAA are both chronic inflammatory diseases of the vascular 
wall and patients with AAA frequently have atherosclerosis,
130
 the diseases have different 
pathogenic mechanisms and therefore the medical approaches differ. Even though the current 
guidelines recommend statin therapy to patients diagnosed with AAA due to their increased 
risk of cardiovascular disease caused by atherosclerosis, the effects of statins have not been 
fully defined yet, and multiple studies show controversial results on the matter. Besides the 
cholesterol-lowering effect, statins also reduce the expression of inflammatory molecules as 
stated before (Figure 7), and this includes downregulation of MMPs.
131
 Treatment with 
atorvastatin in an elastase-induced AAA model suppressed AAA development through 
inhibition of macrophage migration in rats.
132
 Combination treatments with atorvastatin and 
amlodipine, a calcium channel blocker, supressed AAA formation in an angiotensin II 
(AngII)-induced mouse model via inhibition of the Rho-kinase pathway.
133
 A lower mortality 
after AAA rupture and reduced risk of rupture in AAA was associated with statin treatments 
in a nationwide population-based case-control study.
134,135
 A meta-analysis of clinical trials 
from statin-treated AAA patients showed a decreased mortality of 43% and a delayed 
progression of AAA over a five-year period. On the other hand, the same authors failed to 
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show significant reduction in AAA growth rates in patients on statin treatment.
136
 Another 
meta-analysis showed a beneficial effect of statins on preventing the growth of small AAAs, 
which was enhanced as the baseline diameter increased.
137
 Others have shown the lack of 
beneficial effect for both atorvastatin and rosuvastatin in the AngII-infused mouse model of 
AAA.
138
 The evidence that statins should attenuate AAA growth is still unclear, and 
randomised controlled-trials to assess the true impact of statins therapy on the disease are 
unlikely to happen given the high cardiovascular morbidity among patients.
139
 Therefore, 
animal models of AAA are so far the only way to further investigate the effects of plasma 
cholesterol-lowering therapies for the disease development. 
1.6 GENES OF INTEREST 
Atherosclerosis is a complex condition that involves a large number of differentially 
expressed genes which will affect the disease progression and development. Genetic 
alterations could have a major impact in the plaque region as well as in other related 
processes. From the initial steps of the dietary absorption of cholesterol, to its packing into 
lipoproteins in the liver, the modification of the LDL particles within the intima, the immune 
response cascade or the activation of the SMCs from the media, among others, every single 
step is of vital importance. 
In this thesis, two genes previously found to be affected while studying different aspects of 
atherosclerosis and response to cholesterol were taken into examination to elucidate their 
function and real effect within the disease: Lim domain-binding 2 (LDB2) and Poliovirus 
receptor-related 2 (PVRL2). In the next section these two genes will be introduced and 
generally described. They were both found to influence atherosclerosis development by 
altering the migration of leukocytes across the endothelium, although in opposite manners. 
Thus, papers I and II focus on the study of these two genes and their involvement in 
atherosclerosis and TEML using mouse models. 
1.6.1 Lim domain-binding 2 
LDB2, also known as CLIM1, is a gene that belongs to the LIM domain-binding family. It is 
located on human chromosome 4p15.32. All members of this family have two characteristic 
domains: a carboxy-terminal LIM interaction domain and an amino-terminal 
homodimerization domain, and have a conserved sequence for nuclear localization. The LIM 
acronym comes from three homeodomain proteins: lin-11, isl-1 and mec-3. Most LIM 
proteins have more than one LIM domain, and are widely spread in nature.
140
 These proteins 
bind to transcription factors and function as adapter molecules to allow assembly of 
transcriptional regulatory complexes or to block their formation,
141
 and are essential 
regulators of embryonic development.
142-146
 The family of LIM domain-binding proteins 
contains two members: Ldb2/Clim1
144
 and Ldb1/Clim2,
144,147
 both isolated in mice although 
homologs have been isolated in other species (fly, frog, chicken). The human genes have also 
been isolated and cloned and show a high degree of identity with the other species 
homologs.
148,149
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LDB2 is expressed across multiple organs and tissues in the human body.
150
 Genome wide 
association studies have found it to be involved in cytoskeletal organization and cell 
migration during a retinal disease development linked to vision loss.
151
 Besides, it has 
recently been indirectly associated with transcriptional regulation of the endothelium via 
vascular endothelial growth factor (VEGF)-modulation of angiogenesis and vascular 
remodeling.
152
 Gene ontology annotations for biological functions associated with the LDB2 
gene include, besides the already mentioned regulation of transcription, regulation of cell 
migration, kinase activity, cellular component biogenesis, hair follicle development, and 
epithelial structure maintenance. It is also annotated as being part of the nucleus, transcription 
factor complexes and plasma membrane. 
In a previous publication from our group, LDB2 was found to be the most connected gene in 
a transcription factor regulatory network inferred from TEML and atherosclerosis genes in 
CAD macrophages (blood monocytes from CAD patients differentiated to macrophages in 
vitro). In this study, it was found to be expressed in the endothelium, macrophages and 
SMCs in atherosclerotic mouse samples.
153
 In order to elucidate the role of Ldb2 in vivo in 
the disease development, we used a mouse model of atherosclerosis were we have analysed 
knocked out (KO) mice. The results and conclusions from these experiments will be 
discussed in Paper I. 
1.6.2 Poliovirus receptor-related 2 
PVRL2, also known as NECTIN2, CD112, PRR2 or HVEB, is a member of the nectin 
immunoglobulin family and encodes for a single-pass type I membrane glycoprotein. It is 
located on human chromosome 19q13.2 close to the cluster of apolipoprotein genes APOE, 
APOC1, APOC2 and APOC4, a locus which has previously been associated with CAD and 
carotid intima-media thickness.
154,155
 It is expressed ubiquitously in neuronal, epithelial, 
endothelial, and fibroblastic cells, as well as in many tumors.
156
 Its most recognized roles 
include being an entry receptor for viruses,
157
 to coordinate the Sertoli junctions in the 
testis,
158
 being involved in Alzheimer’s disease159,160 and in breast and ovarian cancers,161 in 
addition to participate during neuron synapse formation.
162
 It plays a central role in the 
endothelium as a plasma component of the AJs, where it serves as a cell adhesion 
molecule.
163
 At the endothelium, Pvrl2 binds to afadin, an actin-filament binding scaffold 
protein, through its intracellular region in order to recruit, regulate, and interact with other 
proteins in the AJs (VE-cadherin) or in TJs (JAM-A).
164
  
Up to now, the function of Pvrl2 in CVD has not been extensively studied, although some 
recent publications suggest that it might participate in TEML during disease development by 
promoting leukocyte diapedesis.
165,166
 Lately it has also been shown how its expression was 
induced by oxidized LDL stimulus in the murine aortic endothelium.
167
 Moreover, we 
previously found Pvrl2 to be downregulated when lowering cholesterol in atherosclerosis-
prone mice.
168,169
 This, together with previous knowledge of PVRL2 being part of the AJs in 
the endothelium and appearing to affect TEML, were the main reasons for our interest in its 
further study within the atherosclerosis environment. In order to do so, we generated a Pvrl2 
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KO atherosclerotic mouse model. The results of the experiments that followed will be 
discussed in Paper II. 
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2 AIMS OF THE THESIS 
The main goal of my thesis is to study the cholesterol-lowering effect and assess new 
potential therapy targets for atherosclerosis and CVD. In order to do so, different particular 
mouse models (explained in detail in the following section) have been used. 
The sub-aims to achieve these objectives include:  
- To investigate the role of Ldb2 on atherosclerosis and TEML using the 
atherosclerosis-prone Ldlr
-/-
Apob
100/100
 mouse model (Paper I). 
 
- To investigate the role of the cholesterol-responsive gene PVRL2 on atherosclerosis 
development and its potential role as a novel target for atherosclerosis intervention 
(Paper II). 
 
- To investigate the effect of plasma cholesterol lowering (PCL) and atherosclerosis 
development on AAA formation using the unique mouse model Ldlr
-/-
Apob
100/100
Mttp
flox/flox
Mx1-Cre combined with AngII-induction of AAA (Paper III). 
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3 MOUSE MODELS OF ATHEROSCLEROSIS AND AAA 
The use of experimental animal models in research is of great importance in order to study 
the mechanisms underlying human diseases and  identify potential therapeutic treatments.
170
 
Several animals, including rats, mice, rabbits, hamsters, dogs and pigs are being used in 
cardiovascular research. However murine models are still the first choice due to the small size 
of mice, high fertility, cost-effective maintenance, short gestational time, possibility of 
inducing genetic modifications and easy access.
170,171
 Moreover, mice are fairly 
homogeneous in genetic background, food intake, circadian rhythms and living conditions, 
which minimize confounding factors. Furthermore, a great advantage is also the possibility to 
follow disease progression and stages over a relatively short period of time. 
Two unique mouse models were used to test the hypotheses in the experimental section of the 
publications included in this thesis and they will be described below.  
3.1.1 Atherosclerosis mouse models 
Atherosclerosis is a challenging condition to study in humans due to the length of the disease 
progression. However, in small animals like mice atherogenesis can be easily induced by 
dietary or genetic manipulations that allow studying the whole disease progression in a 
relatively short period of time.
171
 The most common murine models used in this field are 
those with a C57BL/6 background (the inbred strain most prone to develop atherosclerosis) in 
which genetic modifications have been made in the Apoe, the Ldlr or the Apob genes to 
rapidly induce atherosclerosis.
170,172,173
 The differences between these three models are 
discussed in Table 2. Briefly, the Apoe KO, or Apoe-deficient, mice have elevated levels of 
plasma cholesterol on a chow-diet at already 10 weeks of age due to the accumulation of 
VLDL-cholesterol particles.
174,175
 When fed a high-fat diet, their plasma cholesterol levels 
rise up to 2000 mg/dl, which result in the appearance of large atherosclerotic lesions at an 
early age. These lesions develop throughout the aortic tree with fibrous caps, necrotic cores 
and calcification, but without rupture of the plaques or thrombus formation.
176,177
 The Ldlr-
deficient mice fail to develop lesions when fed a chow diet and require a high-fat diet to 
increase their plasma cholesterol levels to around 400 mg/dl. This elevation is due to a rise of 
LDL particles, which makes the model more human-like in the context of hyperlipidemia, 
and the mice develop large atherosclerotic lesions in the aortic root area.
178,179
  
Regarding the total expression of apolipoprotein B, mice express 70% of Apob-48 and 30% 
of Apob-100 in the liver, in contrast to human that express only APOB-100. Apob-100 is the 
main protein in the LDL particles and is needed for them to bind to the LDLR, while Apob-
48 is primarily required for the assembly of CMs in the intestine.
170,173,180
 Modifications in 
the APOB region have traditionally been introduced in mice in two different ways: as a knock 
in from the mutant human APOB gene, or as a targeted mutagenesis of the mouse Apob gene, 
to generate mice that exclusively synthesize APOB-100 or Apob-100, respectively. These 
mice have been crossed with Ldlr-deficient animals to generate the transgenic Ldlr
-/-
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Apob
100/100
 mice that exhibit plasma levels of cholesterol of 300-400 mg/dl on a regular chow 
diet, and develop atherosclerosis along the whole aortic tree.
168,173
 
Table 2. Characteristics of the three principal mouse models of atherosclerosis. 
Genetic modification Cholesterol levels Characteristics 
Apoe
-/-
 CD: 400-800 mg/dl 
HCD: 2000 mg/dl 
Extensive lesions. Cholesterol in VLDL 
particles. 
Ldlr
-/-
 HCD: 400 mg/dl Requires HCD. Large lesions. Cholesterol in 
LDL particles. 
Ldlr
-/-
Apob
100/100
 CD: 300-400 mg/dl Pronounced atherosclerosis. Cholesterol in 
LDL particles. 
CD: chow diet. HCD: high cholesterol diet. 
One of the drawbacks of using mouse models to study atherosclerosis development is that 
none of these models have so far demonstrated plaque rupture as it occurs in humans. 
Another disadvantage is that the plasma lipid profile of mice is different compared to 
humans. However, the plasma lipid profile of the Ldlr
-/-
Apob
100/100
 model mimics the profile 
of patients with familial hypercholesterolemia, and these mice develop advanced 
atherosclerotic lesions on a normal diet.  
This model has also been further modified to include a “genetic switch” which, when 
activated, turns off hepatic lipoprotein secretion: the Ldlr
-/-
Apob
100/100
Mttp
flox/flox
Mx1-Cre 
mouse model. This model allowed us to abruptly lower plasma cholesterol levels by Cre-
induced recombination of the floxed Mttp gene. The induction of Cre expression is regulated 
by the Mx dynamin-like GTPase 1 (Mx1) promoter, which is activated by polyinosinic-
polycytidylic acid (pIpC) injections in an interferon-dependent manner.
181
  
The two atherosclerosis models that have been used for the publications included in this 
thesis are the Ldlr
-/-
Apob
100/100
 and the Ldlr
-/-
Apob
100/100
Mttp
flox/flox
Mx1-Cre. The first model 
(Ldlr
-/-
Apob
100/100
) has been further developed to include modifications in the genes of interest 
(Lbd2 and Pvrl2) for the first two publications (Paper I and II), therefore obtaining an even 
more complex genetic picture. 
3.1.2 Abdominal aortic aneurysm mouse models 
In order to identify potential new treatments and the mechanisms involved in the 
development of AAA in more detail, rodents have been widely used.
182
 Chemical or genetic 
induced AAA in rodents is similar to the human disease, including inflammation, thrombus 
formation, medial degeneration and rupture.
183
 The most commonly used murine models of 
AAA are the angiotensin II infusion in hyperlipidemic mice (Apoe
-/-
 or Ldlr
-/-
) and the 
calcium chloride (CaCl2) chemical treatment. Other models used include elastase-perfusion, 
genetically modified Mmp
-/-
 mice or surgical induction of AAA using vein patches or 
xenografts.
182,183
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In the AngII model, angiotensin II infused into Apoe
-/- 
mice at 500-1000 ng/kg/min via 
subcutaneously implanted mini-osmotic pumps has been shown to promote aortic aneurysm 
formation within a month period,
184
 although not all mice develop AAA.
185
 In this model the 
aneurysm forms in the suprarenal aorta with a number of rupture and dissection cases during 
the first week of AngII exposure.
186
 The AAAs developed in these mice are associated with 
some of the main pathological hallmarks of the disease in humans, including the presence of 
macrophages in the media within days of the infusion, dilation of the lumen, degradation of 
the ECM and thrombus formation within a week; plus subsequent remodelling of the vessel 
and neovascularization.
183
 Also, as in the human setting, the males are more prone to develop 
AAA when using this model.
187
 Importantly, it has been reported that potential increases in 
blood pressure using the AngII model do not influence AAA development.
188
  
In the CaCl2 model, the animals receive a direct periaortic application of CaCl2 between the 
iliac bifurcation and the renal branches which increases the aortic diameter 50-110% within 
2-4 weeks. The formed AAA in this model includes calcium deposition throughout the 
media, disruption of SMCs and elastin, and influx of inflammatory cells. However, in 
contrast with the AngII-infused model, no thrombi are formed.
182,183,189
 
Consequently, in this thesis the AngII-infused model was chosen for the animal experiments 
related to AAA formation. In order to test the hypothesis for paper III, this AngII-induction 
method was performed for the first time (to our knowledge) in the previously mentioned  
Ldlr
-/-
Apob
100/100
Mttp
flox/flox
Mx1-Cre mouse model, and was further combined with the 
cholesterol-lowering treatment. 
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4 PAPERS AND DISCUSSION 
This thesis includes the three publications mentioned at the beginning, named Paper I, II and 
III. The main findings and conclusions drawn from all of them will be briefly presented 
below. The actual papers containing all detailed methods and results can be found attached at 
the end of this thesis. 
4.1 PAPER I - LIM DOMAIN BINDING 2: A KEY DRIVER OF 
TRANSENDOTHELIAL MIGRATION OF LEUKOCYTES AND 
ATHEROSCLEROSIS 
As mentioned before, LDB2 had been found to be the most connected gene in a regulatory 
network of transcription factors inferred from TEML and atherosclerosis genes in CAD 
macrophages in a previous publication from our group.
153
 This means that LDB2 was found 
to be a master regulator of a TEML gene network in relation to CAD, but it does not 
indicate that it was necessarily the main driver of the disease in vivo. LDB2 had not been 
studied in relation to CAD before, so nothing more was known in this regard. All this 
information pointed us towards the direction of validating its potential effect in TEML 
during an atherosclerotic process, which was examined in detail in this publication. In this 
regard, we performed both animal experiments in vivo using our atherosclerosis-prone mice 
(Ldlr
-/-
Apob
100/100
) and cell experiments in vitro. Moreover, a genetic validation in well-
characterized human CAD cohorts was included. 
Regarding the migration experiments carried out with primary leukocytes from mice (either 
from spleen or blood), lack of Ldb2 led to an increased migration, a result opposite to that 
observed in the monocytic THP-1 cell line. Overexpression of LDB2 in THP-1 cells 
resulted in an increase in leukocyte migration, whereas nearly complete depletion by 
siRNA-targeting caused a decrease migration of leukocytes. These conflicting results can 
be explained as a result of the key driver role of the gene. When a main regulator of a gene 
network is completely depleted (KO mice do not have the gene from the beginning of their 
life), downstream genes often lose control and result in increased activity, as it happened 
with the primary leukocytes in our study. When this situation occurs in a more 
physiological condition, as in the THP-1 cells, the effects can be reversed and stimulation 
leads to increased network activity, whereas depletion leads to a loss of network activity. 
This intricate modulation denotes the complex nature of biological processes. 
In addition, in order to study the effect of Ldb2 deficiency in atherosclerosis development 
and to try to pin-point its specific function within the disease we used our athero-prone 
mice crossed with Ldb2 heterozygotes. Loss of this gene in Ldlr
-/-
Apob
100/100
 mice increased 
atherosclerotic lesion size and decreased plaque stability, suggesting an athero-protective 
role for Ldb2 in mice. This was found to be due to increased TEML activity, corresponding 
with our previous hypothesis as a genetic modulator. To confirm that, we performed 
multiple migration assays: air pouch and retinal vasculature models in vivo, leukocyte 
migration in vitro, and ex vivo in situ perfusion of primary leukocytes into our mouse 
model. As stated above, in vitro experiments showed increased migration of leukocytes in 
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the Ldb2-depleted animals. The air-pouch model showed similar results, confirming an 
overall increase of leukocytes for the KO mice, as well as specifically an increase in 
monocytes and macrophages. This was further established with the retina model. Moreover, 
the in situ experiments allowed us to define that the lack of Ldb2 affects the leukocytes and 
not the arterial wall. Therefore, Ldb2-deficiency leads to increased TEML due to its effect 
on leukocytes. Nevertheless, an increase in Vcam-1 expression in leukocyte and the aortic 
wall was found in the KO mice, suggesting an indirect effect that further increases TEML 
by increasing monocyte adhesion to the vessel wall.  
Moreover, a functional SNP of LDB2 (rs10939673) was associated with the extent and risk 
of MI in multiple CAD cohorts, which strengthens the fact that it is a player with an 
important role on atherosclerosis and a potential target that should be investigated further. 
4.2 PAPER II - POLIOVIRUS RECEPTOR-RELATED 2: A CHOLESTEROL-
RESPONSIVE GENE AFFECTING ATHEROSCLEROSIS DEVELOPMENT 
BY MODULATING LEUKOCYTE MIGRATION 
In this study, the atherogenic role of PVRL2, a newly identified cholesterol-responsive gene, 
was investigated. As mentioned previously, PVRL2 had not been studied in the context of 
CVD before, although recent studies had suggested it might play a role in TEML during 
atherosclerotic disease development.
190
 
Pvrl2 was earlier identified in our group as part of a set of genes involved in the prevention of 
atherosclerosis lesion development in response to PCL using the Ldlr
-/-
Apob
100/100 
Mttp
flox/flox
Mx1-Cre mouse model.
168,169
 In the mentioned studies, Pvrl2 was one of the genes 
that responded to PCL in mice just before atherosclerosis regressed both in early (30 weeks of 
age) and mature (40 weeks) atherosclerotic lesions,
169
 and thus was one of the genes 
potentially driving atherosclerosis regression. 
In the present publication, gene expression levels of Pvrl2 in the aortic arch were examined 
during the disease development. Pvrl2 expression was significantly upregulated in mice at 30 
weeks of age, the same time-point as when the atherosclerotic lesions start to expand 
rapidly.
168,169
 Subsequently, we bred Pvrl2
+/-
 mice into our atherosclerosis-prone Ldl
-/-
Apob
100/100
 mice and we found out that the Pvrl2-deficient mice had less atherosclerotic 
lesions and more stable plaques. When examining the plaque composition, macrophages were 
also significantly decreased, whereas no differences were found in SMCs, T cells, 
neutrophils, necrotic core area or proliferating cells.  
As indicated above, PVRL2 may play a role in TEML which could be the cause of the 
decrease in atherosclerosis lesion size in the Pvrl2
-/-
 mice. We investigated the role of TEML 
by different migration assays, using both our mouse model as well as human umbilical vein 
endothelial cells (HUVEC). As expected, we found out that leukocytes migration was 
decreased in the Pvrl2-deficient mice, especially in the monocyte and macrophage fractions. 
Moreover, monocytes seemed to continue to adhere to the endothelium as usual even when 
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Pvrl2 was lacking, which confirmed the hypothesis of the importance of endothelial Pvrl2 
during the transmigration or diapedesis process. 
In order to validate the atherogenic role of PVRL2 in humans, the Stockholm Atherosclerosis 
Gene Expression (STAGE) study was used. In this cohort, PVRL2 was highly expressed in 
the atherosclerotic arterial wall and its expression in this tissue correlated with plasma 
cholesterol levels (total cholesterol, LDL, and VLDL). In contrast, the expression of PVRL2 
in blood was low and no correlations with any CAD phenotypes were found in this tissue. 
Thus, indicating that the expression of PVRL2 in leukocytes per se is not important for the 
atherogenic role of the gene, but rather its endothelial expression. 
Taken together, the results from this publication point towards a pro-atherogenic role of 
PVRL2 through an increase in TEML and thus an increased inflammatory response. In order 
to corroborate this, further experiments would be needed. Nevertheless, these findings 
highlight the importance of TEML as a crucial event during atherosclerosis. TEML is such a 
critical process that overall targeting means it would completely modify the outcome of any 
inflammatory disease. Clearly, inflammation is a much needed process to fight pathogens and 
disease, so completely haltering it is not feasible. Hence, an increased emphasis in TEML 
within disease development is required in order to potentially improve the outcome of 
inflammatory diseases.  
4.3 PAPER III - PLASMA CHOLESTEROL LOWERING IN AN ANGII-INFUSED 
ATHEROSCLEROTIC MOUSE MODEL WITH MODERATE 
HYPERCHOLESTEROLEMIA 
AAA is the tenth most common cause of death in industrialized countries, and prevention 
strategies aiming at reducing the disease progression and risk of aneurysm rupture are 
needed.
86
 The aim of this project was to investigate the relation between the effect of PCL on 
AngII-induced AAA and atherosclerosis. In order to do so, we used our atherosclerosis-prone 
mice with the genetic switch that enables us to lower plasma cholesterol levels by 80% or 
more at any desired time-point, as described earlier (Ldlr
-/-
Apob
100/100
Mttp
flox/flox
Mx1-Cre). To 
our knowledge, this model had never been used before to study AAA development. In order 
to induce AAA formation we used the AngII infusion method explained before in 20 week-
old mice. PCL was performed one week before the AngII infusion, and mice were observed 
during the following 8 weeks prior to sacrifice and organ collection. The mice are divided 
into three groups: a control group were no PCL was induced and with NaCl in the pumps; a 
second group (“AngII” group) were no PCL was induced either but which had AngII to 
promote AAA formation; and a third group (“PCL+AngII” group) were PCL was induced 
just before AngII-containing pumps were implanted to promote AAA formation.  
The sole infusion of AngII into our mice caused a clear increase of atherosclerotic lesions, as 
well as an elevation of inflammatory leukocytes. This was not seen in those mice were PCL 
was induced, which strengthens the importance of high levels of plasma cholesterol for the 
disease development. Moreover, an increase in systemic blood pressure by AngII was 
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detected, and this was prevented by PCL. Still, the effect of AngII on blood pressure is 
debatable, as both increases and decreases have been previously reported. 
Yet, infusion of AngII in our mouse model did not allow for the development of classical 
AAA but rather a modest aneurysmal phenotype with a slight remodelling of the arterial wall. 
Additionally, PCL did not have any detectable effect on AAA formation. The incidence of 
AAA in our model is reported to be between 20-30% after AngII infusion, a much lower 
frequency that the one described using the classical Apoe
-/-
 or Ldlr
-/-
 mouse models (usually 
around 70-80% prevalence), presumably caused by the differences in plasma cholesterol of 
the models..  
Furthermore, collagen content, a characteristic hallmark of AAA progression, was not altered. 
Elastin was found slightly increased after AngII infusion, although this difference was not 
detected when lowering plasma cholesterol. Additionally, the gene expression of selected 
targets usually affected by AAA development was not changed, except for an increase in the 
macrophage marker Cd68 after AngII infusion. This coincides with the previously mentioned 
increase of this cells detected by immunohistochemistry, although this effect is reverted when 
levels of plasma cholesterol are lowered. 
The main reason why AAA could not be achieved is probably, as mentioned above, the 
modest hypercholesterolemia of our mice. As stated before, the classic models to study AAA 
using AngII infusion (Apoe and Ldlr KOs) have much higher plasma cholesterol levels, thus 
reinforcing the statement that high cholesterol levels are needed in order to develop AAA in 
mice. 
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5 FUTURE PERSPECTIVES 
In the past decades, clinical, epidemiological, genetic and experimental studies in humans 
and mice have helped to identify a number of risk factors for CVD. Among the most 
important is cholesterol contained in the LDL particles. Despite the recognition of LDL-
cholesterol as a major risk factor for CVDs and atherosclerosis, and the development of 
powerful LDL-cholesterol-lowering drugs (statins), complications due to atherosclerosis 
remain the first cause of death in the western society. A reason for this is that the 
atherosclerotic plaques are already advanced at onset of therapy as only a minor percentage 
of individuals at CAD/MI risk are qualified to primary statin treatment. Thus, we need to 
better understand markers and signs of early atherosclerosis development and the molecular 
mechanisms that are involved to define those who could benefit from early therapies, and 
we need to seek new therapies to reduce plaque burden besides statin treatment. As briefly 
mentioned before, the newly developed therapies against PCSK9, especially when 
combined with a statin treatment, reveal outstanding results and have shown to decrease up 
to 70% the levels of LDL-cholesterol in patients.
191
 Some ambitious randomized controlled 
clinical trials aiming to validate the overall cardiovascular benefit of targeting PCSK9 are 
still ongoing (such as the “Evaluation of cardiovascular outcomes after an acute coronary 
syndrome during treatment with Alirocumab”, the ODYSSEY Outcomes trial)192 and their 
results are eagerly awaited, while others have just recently been completed (such as the 
“Further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated 
risk”, the FOURIER trial)193 showing a highly significant reduction in major acute 
cardiovascular events of up to 20%. The promising results of these new lipid-lowering 
drugs shed some light into the dark and complex scenario of CVD and its associated 
complications. However, the high cost of these therapies is still a major drawback, which 
encourages the need for further investigations regarding cholesterol-lowering therapies and 
their positive effects.  
In the cardiovascular field, as in many others, every seemingly minor discovery may boost 
research in unexpected ways. In particular, leukocyte transendothelial migration has not 
obtained the attention it needs. Such an important step in any inflammatory event is crucial 
for the development of disease. Understanding all the actors (and not only the major ones) 
that participate in the complex TEML process will open new doors to potential future 
targeted therapies. As previously mentioned, a complete inhibition of this process will be 
counterproductive. The inflammatory response is necessary in order to fight pathogens and 
disease, but this response could potentially be modulated in those sites where is no longer 
providing a beneficial effect. Moreover, anti-TEML therapy could ideally be spatially 
directed towards an organ or tissue, therefore specifically targeting the process at the 
desired place. Some marketed drugs already target key processes in TEML,
194
 such as 
natalizumab, which is directed against a cell adhesion integrin inhibiting leukocyte 
adherence and is prescribed for the treatment of multiple sclerosis.
195,196
 Another drug that 
also targets adhesion integrins involved in TEML is vedolizumab, used for the treatment of 
ulcerative colitis and Crohn’s disease.197 However, as pointed out, this type of treatments 
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entail potentially high associated side effects, as it happens with natalizumab (opportunistic 
viral brain infection that leads to progressive leukoencephalopathy).
196
 Indeed, lack of 
leukocyte migration is consequence of a genetic disease termed “leukocyte adhesion 
deficiency” which leads to impaired wound healing and recurrent bacterial infections.198 
Therefore, one should be extremely careful when interfering with the TEML process.  
In this thesis, two new possible targets, LDB2 and PVRL2 have been examined in the 
context of TEML in atherosclerosis disease. Both seem to play part in the extravasation 
process, although in different ways: LDB2 appears to be a master regulator of the whole 
TEML process, while PVRL2 plays a smaller and more specific role within the diapedesis 
step. In both cases, a complete inhibition would most likely correlate with an increase of 
opportunistic infections. Moreover, specific malfunctions of the tissues and organs where 
they exert their main functions, as both are broadly expressed, would also increase the 
incidence of adverse effects. These facts highlight the importance of developing drugs 
against organ or tissue specific targets. Controlling the migration process in a more specific 
and targeted way could turn these genes into very interesting potential targets. 
Nevertheless, each specific situation should be carefully assessed to minimize off-target 
side effects. Improved experimental models mimicking human disease, such as synthetic 
microfluidic systems or improved animal models, should be further developed in order to 
broaden our knowledge on the molecular and mechanistic cell interactions involved, to 
provide better medical solutions in the future.  
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